Clinical Trial Update: High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating high-dose post-transplant cyclophosphamide plus bortezomib (CyBor) for preventing graft-versus-host disease after allogeneic hematopoie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: NYU Langone Health | Conditions: GVHD | Phase 2 | Status: COMPLETED | Results posted: 2023-12-06